R&D Synthetic Chemistry department of Cadila Pharmaceuticals has a major objective of developing processes of synthesis for various bulk actives and to commercialize the technology up to production scale. We keep in mind the high quality standards required by international pharmaceutical companies and we respect the Intellectual Property Rights of other organizations. This leads us to develop patentable, non-infringing processes that are commercially viable and cost effective so as to be globally competent.

To meet this objective we have a full-fledged world class R&D unit with ultra modern facilities. Our multi - centric research facilities are situated at Dholka, Ankleshwar and at Bangalore.

We have, well equipped Analytical Research Laboratory with all necessary facilities like HPLC, preparative HPLC, HPTLC, FT- IR, DSC, GC, GC Head Space analyzer, LC-MS/MS, Karl Fischer, Polarimeter, UV spectrophotometer, high precision digital melting point apparatus with monitor, Malvern particle size analyzer etc.

We have an excellent and well-equipped library having international journals apart from various technical books and monographs to augment research activity. Our Informatics department is equipped with online search facilities like STN, Scifinder etc.

We have 60 scientists in our R&D Department [Organic Synthesis Division] and 20 analytical scientists [Analytical Research Division] with Ph.Ds, M.Tech, B. Tech, M.Sc and M. Pharm degrees.

We develop multi-step total synthesis of molecule in our chemistry lab up to about 500 gm scale which undergoes optimization and yields improvement till all quality parameters are fixed to result in a validated lab process. This then goes to pilot scale in the same building on a reactor scale from 3 kg scale up to 10 kg scale where all engineering process parameters are fine-tuned and our skilled process engineers establish ruggedness of the technology.

After pilot scale experiments are established, the process is then ready for commercial production. We give maximum attention to produce high quality bulk actives free from related impurities, so as to qualify acceptance criteria laid by ANDA and other stringent regulatory norms.

We are also conscious and have the expertise to provide therapeutically acceptable, stable polymorph for different bulk actives.